Immunochina is committed to the development of CAR-T technology and CAR-T cell products for the treatment of malignant tumors. We have already established a world-class R&D team and will continue to expand our team. We firmly believe that the core competence of our company is motivated by innovative research and development.
Founders of Immunochina, Dr. He Ting, Dr. Lu Xin'an and Dr. Qi Feifei, graduated from School of Life Sciences, Tsinghua University. They have been devoted to the basic and translational research in cancer and immunology, and have mastered multiple CAR-T core techniques.
We believe that humans will find effective ways to combat cancer in the near future. With the development of CAR-T technology, one of the most critical breakthroughs, patients suffering from hematological malignancies will have the opportunity to start a new lease of life.